<DOC>
	<DOCNO>NCT01793649</DOCNO>
	<brief_summary>This randomize , double-blind , cross-over , vehicle-controlled study determine whether GS-5737 2.8 % saline accelerate mucociliary clearance ( MCC ) healthy subject , compare vehicle 2.8 % saline alone .</brief_summary>
	<brief_title>A Phase 1 Study Characterize Effect GS-5737 Enhancement Mucociliary Clearance ( MCC ) Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Body mass index ( BMI ) ≥ 19 ≤ 30 kg/m2 Normal ECG , history evidence myocardial infarction , QT prolongation , ventricular arrhythmia Normal ( abnormal clinically significant ) blood pressure ( BP ) heart rate ( HR ) History lifetime smoke &lt; 5 packyears ( ie , 1 pack per day x 1 year = 1 packyear ) nonsmoker least 60 day duration prior Screening Negative screening test drug abuse ( include alcohol ) Hepatitis B ( HBV ) surface antigen negative Hepatitis C ( HCV ) antibody negative HIV1 , 2 antibody negative Male subject sexually active must willing use highly effective contraception Baseline Visit completion study continue least 90 day date last dose study drug Male subject must refrain sperm donation Baseline Visit completion study continue least 90 day date last dose study drug Females childbearing potential must negative serum pregnancy test Females childbearing potential must agree utilize protocol recommend highly effective contraception method Screening throughout duration study treatment 30 day follow last dose study drug Female subject pregnant lactate History anaphylactic reaction drug Have previously participate investigational trial involve administration investigational compound within 30 day prior study drug dose Presence history extrinsic allergy require treatment ; hay fever allow unless active require treatment within previous 2 month Have donate blood within 56 day study dose Presence history pulmonary disease ( ie , asthma , emphysema , chronic bronchitis , chronic obstructive pulmonary disease ( COPD ) , cystic fibrosis ( CF ) , bronchiectasis , interstitial lung disease ) Major surgery within 6 month Screening Experienced symptom recent acute upper low respiratory tract infection require treatment within 2 week prior Screening Have radiation past year would cause subject exceed recommend limit participate study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Respiratory health</keyword>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
</DOC>